• Active, not recruiting

NCT03650491: Phase 1: A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma

Updated: Jun 22

NCT03650491: Phase 1: A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)


Fortis Therapeutics, Inc.

This study will test the safety and efficacy of FOR46 given every 21 days to patients with relapsed or refractory multiple myeloma.


The name of the study drug involved in this study is: FOR46 for Injection


Sponsor

Fortis Therapeutics, Inc.


Multiple Locations

 

Official Title: A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

First Posted : August 28, 2018


https://clinicaltrials.gov/ct2/show/NCT03650491

 

Drug: FOR46

 

Anti-CD46 ADC FOR46


Anti-CD46 ADC FOR46


Anti-CD46 Antibody-drug Conjugate FOR46 (Code C156416)


ADC FOR46

Anti-CD46 ADC FOR46

Anti-CD46 Antibody-drug Conjugate FOR46

Antibody-drug Conjugate FOR46

CD46-ADC FOR46

FOR 46

FOR-46

FOR46

 

Locations

United States, California

United States, Colorado

United States, Georgia

United States, Maryland

United States, Michigan

United States, Missouri

United States, New York






Posts Archive